These data indicate that survival is obviously shorter in patients with pancreatic cancer with RON and MET co-overexpression, and that TKIs targeting RON and MET, e.g., BMS777607, might be of great significance for treating pancreatic cancer, especially in patients with high RON and MET expression, and for prolonging survival. This evidence concerns the gene MET and familial pancreatic carcinoma.